An observational study in Primary Immune Thrombocytopenia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China — 27 open to participants now, 29 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Institute of Hematology & Blood Diseases Hospital, China.
Among the 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 6 that started in 2023, is one of 2 observational ones, reaches primary completion later than 18 of the 28 other live ones, and was the 12th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →27 of the 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 6–18
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 23 · Phase 3 2 · Phase 4 4
First in 2012; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 60 across the 31 interventional studies, 500 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
5 of the studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06107582Institute of Hematology & Blood Diseases Hospital, ChinaLongitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT07362199Institute of Hematology & Blood Diseases Hospital, ChinaAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | 2027-03 |
| NCT07212322Institute of Hematology & Blood Diseases Hospital, ChinaA Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases | 2027-05-20 |
| NCT07788456Institute of Hematology & Blood Diseases Hospital, ChinaMulti-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia | 2027-05-30 |
| NCT07297563Institute of Hematology & Blood Diseases Hospital, ChinaAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Immune thrombocytopenic purpura (ITP) is a kind of rare childhood disease that involve autoimmune destruction of platelets.The current Pediatric ITP cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in pediatric ITP. The purpose of this study is to analyze the clinical characteristics of Pediatric ITP, the treatment methods, prognosis and prognostic model of these patients in China.
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). ITP is one of the most common hemorrhagic diseases. At present, the treatment response of ITP is not good, and a considerable number of patients need drug maintenance treatment, which seriously affects the quality of life of patients and increases the economic burden of patients. Longitudinal Cohort allows to describe the long-term clinical characteristics of pediatric ITP patients, to study the benefit-risk balance of treatments, including the growing development of targeted therapies and to analyze the prognostic factors and attempts to establish prognostic models.
The study will include pediatric patients diagnosed with primary immune thrombocytopenia in the investigating hospitals, and collect basic information, diagnostic and treatment information from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Pediatric patients who were diagnosed with ITP in the investigating hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immune thrombocytopenia (ITP) : defined according to the international working group criteria
Other: data collection
The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Overall response rate
Overall response rate defined as proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding
Time frame: 3 years
Time to onset response
Time to onset response defined as the time needed for subjects to have a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding
Time frame: 3 years
Duration of response
Duration of response defined as the longest duration for which the subject sustained a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding
Time frame: 3 years
Sustained response rate
Sustained response rate defined as proportion of subjects who keep a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding at 6, 12, 24, 36 months after initial administration of certain treatment in absence of rescue therapy
Time frame: 3 years
Emergency treatment
Percentage of subjects who received emergency treatment after initial administration of certain treatment
Time frame: 3 years
Number of subjects with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP after initial administration of certain treatment
Changes of the subjects' numbers in bleeding score after administration of certain treatment according to the reported bleeding scale for pediatric patients with ITP. The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (\>100 total) and/or \>5 large bruises (\>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb\>2 g/dL or suspected internal hemorrhage;
Time frame: 3 years
Number of subjects with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale after initial administration of certain treatment
Changes of the subjects' numbers in WHO bleeding score after administration of certain treatment according to the reported World Health Organization's Bleeding Scale. The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.
Time frame: 3 years
Recurrence-free survival rate
Time from the start of treatment to the occurrence of a relapse or death event
Time frame: 3 years
Incidence
The incidence of pediatric primary immune thrombocytopenia in China will be described
Time frame: 3 years
Distribution
The population characteristics of pediatric primary immune thrombocytopenia in China will be described
Time frame: 3 years
Prognosis related factors selected from transcriptome data
The prognosis related factors will be selected from transcriptome data and be used to establish prognosis prediction model
Time frame: 3 years
Prognosis related factors selected from proteomics data
The prognosis related factors will be selected from proteomics data and be used to establish prognosis prediction model
Time frame: 3 years
Prognosis related factors selected from metabolomics data
The prognosis related factors will be selected from metabolomics data and be used to establish prognosis prediction model
Time frame: 3 years
Prognosis related factors selected from microbiome data
The prognosis related factors will be selected from proteomics data and be used to establish prognosis prediction model
Time frame: 3 years
Incidence, severity, and relationship of treatment emergent adverse events after treatment
Incidence, severity, and relationship of treatment emergent adverse events after treatment will be analyzed
Time frame: 3 years
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 31 observational studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35. This study's planned 37 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →
Institute of Hematology & Blood Diseases Hospital, China →